BioPharmSignal logoBioPharmSignal

Biotech News

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Acrivon Therapeutics (ACRV)Acrivon TherapeuticsClinical readout

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ACR-2316, a WEE1/PKMYT1 inhibitor currently in Phase 1, demonstrated complete and durable

Related news

ACRVAcrivon Therapeutics2026-08-12 20:05 EST

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

ACRVAcrivon Therapeutics2026-08-05 12:30 EST

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

IDYAIDEAYA Biosciences2026-06-15 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

IDYAIDEAYA Biosciences2026-07-27 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

KYMRKymera2026-06-25 11:00 EST

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

View all latest news

Acrivon Therapeutics

Generative Phosphoproteomics Platform Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines. ACR-368 ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and...

Recent company news

ACRVAcrivon Therapeutics2026-08-12 20:05 EST

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

ACRVAcrivon Therapeutics2026-08-05 12:30 EST

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

ACRVAcrivon Therapeutics2026-07-21 20:30 EST

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

ACRVAcrivon Therapeutics2026-05-21 11:30 EST

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

ACRVAcrivon Therapeutics2026-05-15 20:00 EST

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
2.21 USD
Market cap
67.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States